The latest update is out from Can Fite Bio ( (IL:CANF) ).
Can-Fite BioPharma Ltd. announced a significant clinical development with its drug Namodenoson, which successfully eliminated episodes of decompensated liver cirrhosis in a patient under a compassionate use program. The treatment led to significant symptom improvements and the potential for Namodenoson to provide a therapeutic option for patients awaiting liver transplants. This development addresses a critical need in the liver cirrhosis treatment market, projected to reach $15 billion in the U.S. by 2030, potentially positioning Can-Fite as a key player in this sector.
More about Can Fite Bio
Can-Fite BioPharma Ltd. is an advanced clinical-stage biotechnology company that develops proprietary small molecule drugs targeting oncological and inflammatory diseases. The company is focused on multi-billion-dollar markets in the treatment of cancer, liver diseases, and inflammatory conditions, with lead drug candidates including Piclidenoson for psoriasis and Namodenoson for liver and pancreatic cancers. Can-Fite’s drugs have demonstrated excellent safety profiles in clinical studies.
Average Trading Volume: 14,099,596
Current Market Cap: ILS60.36M
For detailed information about CANF stock, go to TipRanks’ Stock Analysis page.